© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Dibazol traces its roots to early twentieth-century pharmacology. Russian chemists, facing the real medical needs of the young Soviet state, set out to create medications that supported basic physiological functions. They landed on dibazol, known chemically as bendazole, due to its remarkable modulation of smooth muscle tone. For decades, clinicians reached for dibazol when treating vascular spasms and hypertension. Soviet-era textbooks praised it not just for its effectiveness, but for a mechanism that researchers at the time found curious—it enhanced the action of endogenous interferons. Today, dibazol’s legacy carries through as a staple antihypertensive and a launching point for structural analogues in Eastern European labs.
Dibazol isn’t flashy by modern drug standards, but it holds its ground in essential medicine lists. Most commonly, it’s found in tablet and injectable forms, straightforward on appearance with a subtle bitterness. A key reason for its longstanding presence relates to predictable action: it works to relax blood vessels, giving physicans a reliable choice during hypertensive emergencies. In markets where cost and shelf-stability matter, dibazol’s formulation makes distribution simple and storage hassle-free.
Dibazol, or 2-benzylbenzimidazole hydrochloride, presents as colorless to slightly yellowish crystals. Its melting point of about 170–172 °C matches published pharmaceutical standards. The compound dissolves fairly well in both alcohol and chloroform, hardly at all in water—a trait that shapes dosage forms and compounding approaches. Dibazol’s molecular formula, C14H14N2, reflects its small, aromatic structure, granting it good membrane permeability, a key trait for bioavailability. Stability in dry, cool conditions means the product resists decomposition under standard storage, although like many organics, it dislikes light and moisture.
Manufacturers keep dibazol packaging simple yet informative. Labels display the International Nonproprietary Name (INN), chemical structure, strength—commonly 10 mg per tablet or ampoule. Customs and pharmacopeial requirements push for clear identification of batch number, expiration, and excipient details. Assay values usually guarantee not less than 98% active substance by weight, matching international guidelines. Some countries demand QR codes or barcoding to help medical authorities track distribution, a feature that assists with recalls or pharmacovigilance reporting.
Production of dibazol flows from direct alkylation. Chemists react o-phenylenediamine with benzyl chloride under controlled heat, using an alkaline environment to push the substitution forward. The resulting crude dibazol undergoes purification—typically by crystallization from a suitable solvent, often ethanol. Once isolated and dried, the product meets assay requirements via titration or spectrophotometry. Every lot passes tests for impurities: unreacted benzyl chloride, o-phenylenediamine, and related substances must not breach safety limits, a process that demands diligence on the part of manufacturers and drives the evolution of green chemistry techniques.
Dibazol’s benzimidazole scaffold lends itself to modification. Medicinal chemists often explore structure-activity relationships, swapping substituents at both aromatic rings to find new biological profiles. Introducing electron-withdrawing groups delivers fresh antihypertensive agents or shifts activity to antiviral or immunomodulatory effects. Many recent studies focused on boosting water solubility—either by preparing salt forms or attaching polar side chains. Research groups have also married dibazol to other pharmacophores, crafting hybrid molecules that target more than one receptor system in the body. Each molecular tweak unlocks fresh questions about efficacy, pharmacokinetics, and safety.
Dibazol moves through a crowded field of trade names and synonyms. The most common, bendazole, dominates scientific literature. Products sold as Dibazolum or Arudazol pop up in Eastern Europe, with some countries manufacturing it under local brand names to meet regulatory approvals. The systematic IUPAC name—2-benzyl-1H-benzimidazole—rarely turns up outside academic chemistry journals. Generic listings ensure healthcare workers recognize all variants, lowering the risk of duplication or confusion in hospital formularies, a critical issue in international travel medicine.
Regulatory agencies enforce strict protocols for dibazol manufacture and administration. Workers in pharmaceutical plants wear protective gear to guard against skin and respiratory contact, especially during the handling of alkylating intermediates. Pharmacovigilance departments log all adverse events reported by health professionals, and periodic updates inform hospital pharmacies about rare side effects or contraindications. Standard treatment algorithms advise caution in patients with liver or kidney impairment—these organs excrete dibazol or process its metabolites, so impaired function increases risk. Education for both clinicians and patients matters greatly to prevent dosing mishaps or allergic reactions, especially since dibazol sometimes appears in compounded preparations alongside other antihypertensives.
Most people come across dibazol in clinics addressing acute elevated blood pressure. Emergency medicine departments stock ampoules for rapid intravenous push. Rural clinics value dibazol tablets because their shelf life spans harsh weather and disrupted refrigeration. In neurology, dibazol once earned a reputation for treating peripheral vascular disorders, including Raynaud’s phenomenon, due to its smooth muscle relaxation. Some researchers explored its use in immune support protocols, especially in viral hepatitis management. These days, competition from newer drugs has narrowed its range, yet essential medicine lists in several post-Soviet states still include it because it fits into both primary and secondary care.
Academic and industrial teams still investigate dibazol derivatives. They aim for molecules that hold onto the parent’s antihypertensive power while shedding side effects. Some research turns toward immunomodulation, hoping to harness dibazol’s capacity to increase endogenous interferon release and thereby blunt viral replication. Other groups publish on dibazol as a scaffold for anti-tumor agents, inspired by structural similarities to other benzimidazoles already on the market for different indications. Modern R&D relies on computational chemistry, letting scientists screen modifications in silico before synthesizing compounds in the lab. Universities in Russia and China, in particular, supply a steady stream of dissertations focused on dibazol, proof that this old drug keeps fueling new ideas.
Toxicologists long ago mapped dibazol’s safety window. High-dose studies in rodents and rabbits show a low risk of organ-specific toxicity, provided dosing doesn’t run wild. Oral LD50 values rank among the safer antihypertensives, but this doesn’t grant dibazol a free pass. Parenteral overdose brings transient central nervous system sedation, blood pressure drops, and—at sky-high doses—muscle tremors. In humans, hypersensitivity reactions rate as uncommon. Hospital pharmacists keep tabs on cumulative exposure in patients with chronic therapy and report rare cases of liver enzyme elevation within pharmacovigilance networks. Ongoing studies use contemporary models, such as zebrafish embryos and 3D cell cultures, to look for genotoxic and developmental side effects. Safety monitoring adapts as regulatory expectations ratchet up and as new automated toxicity screening makes its way into pharmaceutical testing.
No matter how crowded the antihypertensive field becomes, dibazol retains certain appeal. Countries with resource constraints and rising rates of hypertension value drugs that come cheap, store well, and get the job done with predictable side effects. Pharmacogenomic advances may one day tailor dibazol or its analogues for populations with rare enzyme variants, boosting response or trimming side effects. Combination therapy represents another path: pairing dibazol’s molecular skeleton with other antihypertensive or immunomodulating groups hints at future fixed-dose options. Green chemistry trends also push manufacturers to shift toward less polluting production routes, aiming to future-proof an old drug for new environmental standards. If history offers any guide, dibazol will continue to inspire not just pharmacologists and synthetic chemists but frontline clinicians looking for reliable tools in medicine’s daily challenges.
Dibazol, also known as Bendazol, sits on drugstore shelves in many countries with a long history backing its use. The roots of this medication trace back to the Soviet era, where doctors often turned to it for issues related to blood pressure and muscle spasms. These days, it doesn’t grab international headlines, but plenty of folks, especially in Eastern Europe and parts of Asia, still get a prescription filled each month. The name means little to someone outside of this region, but for patients and physicians here, Dibazol sparks memories of a staple treatment option.
For years, Dibazol has been a go-to remedy for what many people call “spastic conditions.” The body acts up, muscles tighten or cramp, and doctors trust this medication to help settle things down. The main job Dibazol covers—helping vessels relax and reduce blood pressure—carries weight in health care, especially in places where modern antihypertensives cost a small fortune or can’t be found as easily. Some Russian and Eastern European clinics reach for it when a patient’s blood pressure jumps high during a stressful moment, or when leg muscles refuse to let go after a long walk.
Beyond just muscle spasms, some researchers explored Dibazol’s use in boosting immune response, particularly for older adults. This topic drifts through local health journals more than it does international ones. Studies suggest a possible role in fighting viral infections, but the evidence stays thin. Anecdotes float around, and some doctors bring it up for added support in colds or flu, especially when other options look out of reach. Solid proof still has to catch up to these stories.
Anyone growing up in a Russian-speaking country has probably heard a grandmother mention Dibazol at least once, either for nerves or for wild swings in blood pressure. The experience for most people stays mild—few strong side effects, a bit of relief, sometimes nothing at all. Doctors tend to use Dibazol as an extra rather than a front-line defense. They know not every muscle problem or pressure spike asks for it. Even so, the ease of access makes overuse a risk. Some folks get tempted to try it on their own, skipping a doctor’s advice, or treating every ache and pain with it “just in case.” This approach doesn’t match modern medical guidelines.
No one can ignore the new generation of blood pressure and spasm medications. Clinical research now favors options that offer clearer evidence and broader testing. Still, the story of Dibazol reflects the bigger picture in health care around the world. Sometimes, affordability and tradition guide choices as much as science. For people facing tough economic realities, a well-known medicine brings comfort. Health systems that prioritize patient education—teaching which situations call for Dibazol and which ones need a different approach—make all the difference. Open conversations between patients and clinicians will always outlast any single medication’s popularity.
Dibazol, also known as bendazole, shows up in clinics for treating high blood pressure and muscle spasms. Old Soviet medical kits often had it right alongside bandages and iodine, a reflection of its widespread use in Eastern Europe and Central Asia. Doctors valued it for its quick action on blood vessels, giving relief to folks when their heads pounded or their nerves fired the wrong signals.
I’ve met a handful of folks who took Dibazol for the first sign of a migraine. They expected calm and instead felt dizzy, light-headed, or even faint. Reports match those experiences. The drug works by relaxing blood vessel walls, dropping blood pressure. This rapid drop causes some people to lose balance, feel weak, or get a flush of warmth spreading over the face and neck. Nausea sometimes follows. My own grandmother once landed in bed the entire afternoon after a single dose, swearing off the pills forever.
Allergic reactions deserve special attention. Hives, sudden swelling, and difficulty breathing all signal a problem. A trip to the ER becomes the only option in those situations. Though rare, these reactions happen. People with sensitivities or allergies to medications often stand in the line of risk. Dibazol, like many drugs, can cause shifts in liver enzymes and even disrupt heart rhythms in vulnerable people. People with chronic illnesses, especially liver or kidney disease, need to watch for these problems. Basic checks—blood pressure, pulse, blood tests—give a clearer picture of how well the body tolerates the medicine.
Many get surprised to learn that Dibazol revs up when used alongside other blood pressure medicines or muscle relaxants. Twice I’ve seen friends, both over sixty, complain about feeling "out of this world" after combining pills. One had a close call, blacking out while shopping for groceries. It turns out that what starts as a handy remedy for tension or cramping can push blood pressure down too far. This problem magnifies in older adults, who carry more prescriptions in their pillbox.
Pediatricians and OB-GYNs stay cautious for a good reason. Kids react differently to medication than adults. Pregnant women protect not only themselves but their unborn babies. Testing in these groups remains limited, so doctors rarely reach for Dibazol unless they see no other way. Risks of uncontrolled blood pressure in pregnancy include harm to mother and child, so expert guidance becomes crucial here.
Doctors emphasize starting with a small dose and increasing only if needed. Monitoring during the first hour after taking Dibazol gives people a chance to catch unexpected drops in blood pressure. Preventing trouble sometimes means skipping the medicine altogether, especially if other treatments work with fewer side effects.
Handing over a new prescription always includes a conversation. Have a list of current medications ready. Tell your doctor if you’ve had reactions before. Simple steps, but they keep the spotlight on safety, not surprises. Staying alert and respecting the power in the little white tablet beats regret every day.
Dibazol, known in many countries as Bendazole, turns up often in discussion around managing high blood pressure, muscular spasms, and certain neurological problems. Many years ago, my grandmother’s doctor wrote her a prescription for Dibazol. Back then, I wondered what exactly that little white tablet did, and what she should look out for while taking it. Talking with doctors since then, I’ve learned the rules with Dibazol stay pretty straightforward but absolutely require some diligence.
Dibazol tablets typically come in a low dosage—commonly 20 mg. Adults often get a twice or three times daily dosage, depending on the severity of their condition. If a doctor advises a different frequency, it usually matches specific medical needs or other health issues at play. Skipping doses or popping extra pills to make up for a missed one can really throw off your treatment. Too much dibazol won’t make symptoms disappear faster, and it brings a higher risk of side effects, like dizziness or low blood pressure spells.
Some folks—especially those dealing with kidney, heart, or liver problems—may need a different dose or more vigilant monitoring. Children and pregnant women fall under special clinical consideration, and sharing adult guidance with them just won’t cut it.
Always swallow Dibazol tablets whole, with half a glass of water. Crushing or splitting can alter the drug’s absorption profile, which can unexpectedly affect how it works. Most people take their dose before meals, unless their physician gives different instructions. Food can sometimes change absorption speed, so set a regular routine that fits your doctor’s advice.
Some patients in a hospital receive Dibazol as an injection. This step lies entirely in the hands of trained medical staff. If you ever see a nurse or doctor preparing an injectable form, rest assured that it requires close supervision to avoid sudden drops in blood pressure.
Mild side effects like fatigue, slight nausea, or headaches pop up most often. For most, these settle after a day or two. Rare reactions—sudden muscle weakness, rash, or palpitations—should send you straight to a physician. If you ever feel faint after a dose or notice any allergic reaction, don’t chalk it up as just a normal adjustment. Call your doctor or visit a clinic. Delaying action increases risk.
Dibazol plays well with some drugs but can interact dangerously with others. Taking medications for high blood pressure or heart disease? Let your doctor know before starting Dibazol. Even common painkillers or over-the-counter cold remedies can have unpredictable effects if combined without professional input. My own experience trying to blend prescription drugs—without a pharmacist’s advice—once landed me in a doctor’s office.
Open conversation about medical history and current prescriptions means you stand a better chance of feeling healthy during treatment. Doctors look beyond the symptoms to spot issues that might not seem obvious at first. Keeping up with scheduled checkups includes sharing every side effect and every change, no matter how small it might seem.
Store the tablets in a dry, room-temperature place away from children. Never use a friend’s leftover pills or change your dose just because you feel better. If you run out, ask for a new prescription. Skipping doctor advice risks both your own health and the trust you build with your healthcare provider.
Careful following of directions sets the stage for Dibazol to play its role without unexpected problems.
Dibazol, known by its generic name bendazole, has been used for many years as an antispasmodic and vasodilator. It’s prescribed to lower blood pressure, relax muscles, and sometimes to boost the body’s immune system. Across several countries, it still finds a place in treating hypertension and certain muscle-related conditions. Pregnant people dealing with high blood pressure often feel anxious about the potential risks of any medication they’re prescribed, and it’s natural to ask if Dibazol can be counted on as a safe option.
The safety of drugs in pregnancy comes with a huge responsibility. We trust doctors to weigh both the benefits and possible dangers. With Dibazol, the research is nowhere near as in-depth as with more common medications like methyldopa or labetalol. There aren’t large human trials looking specifically at Dibazol’s effects on pregnant women or developing babies. Most reports point out that this drug hasn’t sparked any well-documented problems in animals, but scientists still can’t say for sure if the same holds true for humans. In medicine, what we don’t know often means we need to tread carefully.
Doctors lean toward prescribing medicines with a solid safety record in pregnancy. Methyldopa, labetalol, and nifedipine have been studied over many years and usually rank ahead of less-understood options. These choices come with clear guidelines, and there’s more confidence in how they’ll affect both mother and child. I’ve seen the stress parents go through when told something about their treatment lacks concrete answers. Most just want to make choices that stack the odds in favor of a healthy delivery, and that includes trusting medications backed by broad clinical experience.
Pregnancy brings a wave of changes and decisions that can leave anyone feeling overwhelmed. Open discussions between patient and healthcare provider matter just as much as written studies. People come in with their own health stories — some might not respond well to standard drugs or could have allergic reactions. In those rare cases where no proven alternatives work, doctors sometimes weigh the use of less-studied medications like Dibazol. It involves a frank talk about what’s known, the gaps in research, and exactly why there’s a need to take that risk.
Healthcare guidance draws on real-world data, not just textbooks. For drugs in pregnancy, the gold standard comes from human research, surveillance after approval, and well-logged case reports. Large organizations like the World Health Organization and American College of Obstetricians and Gynecologists do not list Dibazol as a preferred medicine for managing blood pressure in pregnant patients. This absence speaks volumes. The gap in human studies on Dibazol during pregnancy steers most clinicians toward medicines with better-established safety.
There’s no denying drug safety in pregnancy deserves more attention. Women are rarely included in clinical research at the same rate as men, and pregnancy complicates things further. Better data helps reduce uncertainty and eases the minds of future patients. Until those answers show up, taking steps to avoid unproven treatments matters. Medical professionals need to stay up-to-date, ask questions about side effects, and press for ongoing research. That improves care for everyone, not just those sitting in exam rooms today.
Anyone taking more than one medicine, prescription or over-the-counter, deserves to know about possible drug interactions. The medicine Dibazol shows up in some parts of the world as a muscle relaxant and blood pressure aid. Using it on its own may work fine in healthy people, but health rarely fits into neat boxes. Sometimes, a new prescription—for blood pressure, a cold, or even anxiety—gets added to the routine. This is where good information keeps surprises away.
I’ve watched busy people walk into the pharmacy, new script in hand, not knowing what might cross paths in their bodies. They trust their doctor and their pharmacist. Some bring a list of what they’re already taking, some don’t. One elderly man once said, “My wife takes so many pills, she could open a shop.” His concern was real: “Can these all work together, or will one mess up the other?” That question sticks in my mind, especially knowing many folks don’t realize what can go unnoticed when mixing medications.
Dibazol can lower blood pressure. Other drugs, like ACE inhibitors (think lisinopril) or beta blockers (like atenolol), can drop it further. Too much of a good thing, and dizziness or fainting may follow. Some anti-anxiety drugs, sleep aids, or alcohol could make that risk worse, upping the chance of dangerous falls in older folks.
Doctors prescribe Dibazol for muscle spasms in some settings, like after a stroke. Mixing it with muscle relaxants—baclofen, tizanidine—can leave someone groggy, weak, or accident-prone. Even ordinary painkillers or cold meds may interact, since the body has only so many ways to handle chemicals. It’s not just prescription pills that matter: herbal remedies and supplements sometimes pull their own tricks. Some supplements could change how the liver breaks down Dibazol or other meds, leading to less effect or unexpected side effects.
Researchers have tracked cases of low blood pressure and excessive tiredness after blending Dibazol with other muscle relaxants or heart medicines. The World Health Organization lists Dibazol among drugs with possible drug-drug interactions. Mixing medicines always deserves a careful look, especially if kidney or liver function isn't perfect—like in people living with diabetes, high blood pressure, or advancing age. The body processes drugs more slowly with weakened kidneys or livers, meaning small doses can hit harder than expected.
Medication safety boils down to honest talk. Taking the time to ask a pharmacist or doctor, “Will this work with what I already take?” goes a long way. Keeping a personal list of medicines, both prescribed and over-the-counter, gives a solid starting point. Bringing that list to every visit or pharmacy switch makes life easier for everyone.
Some health apps can remind people about possible interactions, but they never replace a real chat with a professional. Families play a role, too—checking in on elderly relatives, asking how they feel after a new medicine, watching for dizzy spells or tiredness.
People don’t always realize how everyday medicines can quietly fight each other, or work too well in tandem. Trust builds with information. Pharmacovigilance—watching for drug reactions—only works if people feel empowered to ask questions and share what’s in their medicine cabinet. That’s the best way to keep surprises (and hospital visits) off the calendar.
| Names | |
| Preferred IUPAC name | 2-(1H-benzimidazol-2-yl)ethan-1-amine |
| Other names |
Bendazole Dibazole |
| Pronunciation | /ˈdɪbəˌzɒl/ |
| Identifiers | |
| CAS Number | 86-92-0 |
| 3D model (JSmol) | `3D model (JSmol) string for Dibazol:` `CCN(CC)CCNC1=CC=NC2=NC=CC=C12` |
| Beilstein Reference | 1209240 |
| ChEBI | CHEBI:4953 |
| ChEMBL | CHEMBL1407 |
| ChemSpider | 3229 |
| DrugBank | DB08933 |
| ECHA InfoCard | 03b77fa7-cfbf-4b34-8796-544496ce0f89 |
| EC Number | 3.5.4.4 |
| Gmelin Reference | 7816 |
| KEGG | C06845 |
| MeSH | Dibazol |
| PubChem CID | 2176 |
| RTECS number | UJ4375000 |
| UNII | 3M2Z416B0B |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C8H10N4 |
| Molar mass | 261.29 g/mol |
| Appearance | White or white with a yellowish tint powder. |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Soluble in water |
| log P | 0.44 |
| Vapor pressure | Negligible |
| Acidity (pKa) | 7.6 |
| Basicity (pKb) | 10.30 |
| Magnetic susceptibility (χ) | −14.0×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.642 |
| Dipole moment | 2.61 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 221.0 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -104.8 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -3504 kJ/mol |
| Pharmacology | |
| ATC code | C04BX01 |
| Hazards | |
| Main hazards | May cause irritation to the eyes, skin, and respiratory tract. |
| GHS labelling | GHS07 |
| Pictograms | Medicinal product subject to medical prescription / Keep out of the sight and reach of children |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | Keep out of reach of children. If swallowed, seek medical advice immediately and show this container or label. Avoid contact with eyes and skin. Store in a cool, dry place away from direct sunlight. |
| NFPA 704 (fire diamond) | 1-0-0 |
| Lethal dose or concentration | LD₅₀ (rat, oral): 940 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Dibazol: "Dibazolum LD50 (rats, i/v) = 220 mg/kg |
| NIOSH | Not classified |
| PEL (Permissible) | PEL (Permissible) for Dibazol: 2 mg/m³ |
| REL (Recommended) | 0.002 g |
| IDLH (Immediate danger) | Not listed |
| Related compounds | |
| Related compounds |
Bendazole hydrochloride Papaverine Drotaverine No-Spa Papazol |
